Cargando…
636. Immunogenicity, Safety and Tolerability of a Booster Dose of Clostridium difficile Vaccine and 4 Year Antibody Persistence
BACKGROUND: Clostroidides difficile (C difficile) is a common cause of antibiotic-associated diarrhea. To date, there is no vaccine to prevent C. difficile infection (CDI). This extension of a phase 2 study explores the immunogenicity, safety, and tolerability of a 4th dose, and antibody persistence...
Autores principales: | Remich, Shon A, Kitchin, Nicholas, Pride, Michael W, Anderson, Annaliesa S, Li, Ping, Webber, Chris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778284/ http://dx.doi.org/10.1093/ofid/ofaa439.830 |
Ejemplares similares
-
A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years
por: Kitchin, Nicholas, et al.
Publicado: (2020) -
12. Randomized Studies of Two Clostridioides (Clostridium) difficile Vaccine Formulations
por: Lawrence, Jody, et al.
Publicado: (2020) -
Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliC
por: Ghose, Chandrabali, et al.
Publicado: (2016) -
Safety and immunogenicity of Clostridium difficile toxoid vaccine in Japanese adults
por: Matsuoka, Osamu, et al.
Publicado: (2017) -
636. A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Quadrivalent Dengue Vaccine (V181)
por: Russell, Kevin, et al.
Publicado: (2021)